lp8

LP8 is a novel inhibitor of Trypanosoma cruzi CYP51.

Sotagliflozin (LX-4211, LP-802034) is an oral dual inhibitor of sodium-glucose cotransporter 1/2 (SGLT1/SGLT2) (SGLT2, IC₅₀ ≈ 1.8 nM; SGLT1, IC₅₀ ≈ 36 nM) used as an antidiabetic agent. Sotagliflozin is used in research on cardiovascular disease and diabetes.

Antibiotic LL-P880y is a useful organic compound for research related to life sciences. The catalog number is T124885 and the CAS number is 41206-21-7.

LP-856866 is an orally active ACSL5 inhibitor, exhibiting IC50 values of 8 nM for mouse ACSL5 and 4 nM for human ACSL5, while demonstrating IC50 values of 6 nM for mouse ACSL1 and 17 nM for human ACSL1. It induces delayed gastric emptying, enhances GLP-1 release, reduces food intake, decreases body weight and fat mass, preserves lean body mass, improves glucose homeostasis, boosts insulin sensitivity, reduces hepatic fat accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable for studies on diet-induced obesity.

LL P880 beta is a fungal metabolite.